» Articles » PMID: 26390437

Increased Urinary Exosomal MicroRNAs in Patients with Systemic Lupus Erythematosus

Overview
Journal PLoS One
Date 2015 Sep 22
PMID 26390437
Citations 85
Authors
Affiliations
Soon will be listed here.
Abstract

There is increased interest in using microRNAs (miRNAs) as biomarkers in different diseases. Present in body fluids, it is controversial whether or not they are mainly enclosed in exosomes, thus we studied if urinary miRNAs are concentrated inside exosomes and if the presence of systemic lupus erythematosus with or without lupus nephritis modifies their distribution pattern. We quantified specific miRNAs in urine of patients with systemic lupus erythematosus (n = 38) and healthy controls (n = 12) by quantitative reverse-transcription PCR in cell-free urine, exosome-depleted supernatant and exosome pellet obtained by ultracentrifugation. In control group, miR-335* and miR-302d were consistently higher in exosomes than in exosome-depleted supernatant, and miR-200c and miR-146a were higher in cell-free fraction. In lupus patients, all urinary miRNAs tested were mainly in exosomes with lower levels outside them (p<0.05 and p<0.01, respectively). This pattern is especially relevant in patients with active lupus nephritis compared to the control group or to the SLE patients in absence of lupus nephritis, with miR-146a being the most augmented (100-fold change, p<0.001). Among the exosomal miRNAs tested, only the miR-146a discriminates the presence of active lupus nephritis. In conclusion, urinary miRNAs are contained primarily in exosomes in systemic lupus erythematosus, and the main increment was found in the presence of active lupus nephritis. These findings underscore the attractiveness of exosomal miRNAs in urine, a non-invasive method, as potential renal disease markers.

Citing Articles

Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches.

Saegusa K, Tsuchida Y, Komai T, Tsuchiya H, Fujio K Int J Mol Sci. 2025; 26(3).

PMID: 39940698 PMC: 11816971. DOI: 10.3390/ijms26030929.


Present and Future Use of Exosomes in Dermatology.

De A, Chakraborty D, Agarwal I, Sarda A Indian J Dermatol. 2024; 69(6):461-470.

PMID: 39678744 PMC: 11642453. DOI: 10.4103/ijd.ijd_491_23.


Panel miRNAs are potential diagnostic markers for chronic kidney diseases: a systematic review and meta-analysis.

Garmaa G, Nagy R, Koi T, Do To U, Gergo D, Kleiner D BMC Nephrol. 2024; 25(1):261.

PMID: 39138396 PMC: 11323638. DOI: 10.1186/s12882-024-03702-y.


Future embracing: exosomes driving a revolutionary approach to the diagnosis and treatment of idiopathic membranous nephropathy.

Wang L, Wang J, Xu A, Wei L, Pei M, Shen T J Nanobiotechnology. 2024; 22(1):472.

PMID: 39118155 PMC: 11312222. DOI: 10.1186/s12951-024-02633-y.


Exosome nanovesicles: biomarkers and new strategies for treatment of human diseases.

Xu C, Jiang C, Li Z, Gao H, Xian J, Guo W MedComm (2020). 2024; 5(8):e660.

PMID: 39015555 PMC: 11247338. DOI: 10.1002/mco2.660.


References
1.
Wang H, Peng W, Ouyang X, Li W, Dai Y . Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res. 2012; 160(3):198-206. DOI: 10.1016/j.trsl.2012.04.002. View

2.
Luo Y, Wang C, Chen X, Zhong T, Cai X, Chen S . Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem. 2013; 59(4):658-66. DOI: 10.1373/clinchem.2012.195297. View

3.
Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y . MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009; 60(4):1065-75. DOI: 10.1002/art.24436. View

4.
Te J, Dozmorov I, Guthridge J, Nguyen K, Cavett J, Kelly J . Identification of unique microRNA signature associated with lupus nephritis. PLoS One. 2010; 5(5):e10344. PMC: 2867940. DOI: 10.1371/journal.pone.0010344. View

5.
Barutta F, Tricarico M, Corbelli A, Annaratone L, Pinach S, Grimaldi S . Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One. 2013; 8(11):e73798. PMC: 3817183. DOI: 10.1371/journal.pone.0073798. View